Interestingly, downregulation of SFRP1 expression rendered triple negative breast cancer cell line MDA-MB-468 more resistant to the chemotherapeutic agents paclitaxel, cisplatinum and doxorubicin (Figure 2B, left column). Here, SFRP1 is linked to triple-negative breast carcinoma.